For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

Predicting Response to Your Myelodysplastic Syndromes (MDS) Treatment

Clinical Trial Details

The primary aim of this study is to explore and characterize the methylation profiles of MDS patients via an online, community outreach process, with CRUSH!!MDS as a platform.  We aim to characterize the methylation profiles of MDS patients who have previously failed hypomethylating agents.  We will characterize methylation profiles of subjects granulocytes in peripheral blood, utilizing methylation platform developed by Dr. Joseph Scandura at Weill Cornell Medicine.

Key Eligibility: 
  • At least 18 years of age with pathologically confirmed MDS (<20% blasts in bone marrow peripheral blood or both)
  • Must have received at least 4 cycles of decitabine-based or 6 cycles of azacitidine-based therapy and are either refractory to, relapsed after or intolerant to prior therapy with either agent
  • Able to understand and to provide written informed consent
  • No presence of acute myeloid leukemia (AML)

Study contact by location

Upper East Side - Manhattan


Yulia Dault, RN
(212) 746-4829

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group